Request Demo

Last update 08 May 2025

Cardiomyopathy, Right Ventricular Dilated

Last update 08 May 2025

Basic Info

Synonyms

CARDIOMYOPATHY, RIGHT VENTRICULAR DILATED, Cardiomyopathy, Right Ventricular Dilated, 心肌病，右心室扩张

Introduction-

Clinical Trials associated with Cardiomyopathy, Right Ventricular Dilated

NCT04345796

/ CompletedPhase 3IIT

Multicenter, Randomized, 2 x 2 Factorial, Phase 3 Study to Assess the Efficacy of Carvedilol and Empagliflozin on Improvement of Right Ventricular Remodeling in Patients With Severe Functional Tricuspid Regurgitation

Functional tricuspid regurgitation (TR) has been regarded as a secondary phenomenon of heart failure (HF), mitral valve (MV) disease or atrial fibrillation. Regardless of left ventricular (LV) function or pulmonary artery pressure, presence of moderate or greater functional TR is associated with poor prognosis. When a patient develops functional TR, it causes RV dilation and tricuspid annular enlargement, which also lead to deterioration of TR. A vicious cycle of significant TR, RV volume overload, tricuspid annular dilation and consequent aggravation of TR is accepted as a main determinant of the poor clinical outcome of patients with TR. Therefore, therapies that induce reverse remodeling of the RV and consequently reduce TR, may improve clinical outcomes. However, there have been no proven medical therapies for TR. The investigators hypothesize that carvedilol or empagliflozin is effective on improving RV remodeling in patients with functional severe TR and try to examine this hypothesis in a multicenter, 2x2 factorial, and randomized comparison study using cardiac MRI.

Start Date15 Feb 2021

Sponsor / Collaborator

Asan Medical Center

[+1]

NCT03344159

/ CompletedPhase 4IIT

Spironolactone Therapy in Chronic Stable Right HF Trial

The purpose of this study is to evaluate the safety, tolerability and mechanistic effects of spironolactone, an aldosterone receptor antagonist, on sympathetic nervous system activity and right heart function and remodeling in patients with chronic right heart failure.

Start Date01 Apr 2018

Sponsor / Collaborator

Ottawa Heart Institute Research Corp.

100 Clinical Results associated with Cardiomyopathy, Right Ventricular Dilated

100 Translational Medicine associated with Cardiomyopathy, Right Ventricular Dilated

0 Patents (Medical) associated with Cardiomyopathy, Right Ventricular Dilated

980

Literatures (Medical) associated with Cardiomyopathy, Right Ventricular Dilated

01 Apr 2025·Turkish Journal of Emergency Medicine

Validation of the echoSHOCK protocol for diagnosing the cause of shock in patients arriving at the emergency department

Article

Author: Bairwa, Archana ; Jayachandran, Sreejith ; Shankar, Takshak ; Ameena, M. S. Salva ; Jose, Jewel Rani ; Kaeley, Nidhi ; Sasidharan, Parvathy ; Yadav, Jitendra Kumar

OBJECTIVES:Nontraumatic undifferentiated shock is difficult to manage in the emergency department due to unclear causes, lack of history, and rapid patient deterioration. Timely and appropriate resuscitation is crucial, but both inadequate and excessive resuscitation increase mortality risks. Focused cardiac ultrasound (FoCUS) offers a timely and noninvasive cardiac assessment. The echoSHOCK protocol is derived from FoCUS and improves the ability to identify the etiology of shock in patients at the emergency department. This study’s primary objective was to validate the echoSHOCK protocol for diagnosing the cause of shock in patients arriving at the emergency department. This study’s secondary objective was to determine the prevalence of different etiologies of shock in patients arriving at the emergency department.METHODS:Adult patients presenting to the emergency department in shock were included in the study after informed consent was obtained. The shock was defined as a systolic blood pressure of <90 mmHg or a mean arterial pressure of <65 mmHg with signs of poor tissue perfusion. Each patient underwent a detailed history, physical examination, and standard investigations. Clinicians reported a presumed etiology and management plan with a confidence level (0–10). The echoSHOCK protocol was then executed and its results were recorded with the respective confidence levels. The protocol used a phased array probe in B-mode solely and assessed left ventricle function, compressive pericardial effusion, right ventricular dilatation, interventricular septum flattening, and indicators of hypovolemia. The time taken to perform the protocol and the difficulty level were noted. An expert panel followed the patient till hospital discharge and provided the final diagnosis and intervention.RESULTS:The study enrolled 223 patients with a mean age of 49.12 years. The echoSHOCK protocol showed a 94.2% agreement with expert panel diagnoses on the cause of shock and proposed interventions, with a statistically significant near-perfect agreement (Cohen’s Kappa −0.896, P < 0.001 and 0.897, P < 0.001, respectively). In contrast, the agreement between the clinical assessment, routine workup, and expert panel diagnoses was 46.2% on the cause of shock and 45.7% on the proposed interventions, respectively. The echoSHOCK protocol’s median feasibility score was 7 (interquartile range [IQR]: 6–8), and its median performance time was 7 min (IQR: 6–10). Confidence in diagnoses was significantly higher with echoSHOCK (mean: 7.14) than with clinical examination (mean: 4.47) (Wilcoxon Test: P <0.001).CONCLUSION:The echoSHOCK protocol rapidly identifies shock etiology in patients at the emergency department. This aids in rapid resuscitation.

01 Mar 2025·Journal of Medical Imaging and Radiation Oncology

Pulmonary veno‐occlusive disease: A systematic review of risk factors, clinical presentation, diagnostic investigations, treatment outcomes and prognostic factors

Review

Author: Hakak‐Zargar, Benyamin ; Thong, Louisa P ; Burns, Andrew T ; Harisis, George N ; Ha, Francis J ; Ellis, Samantha J

SummaryPulmonary veno‐occlusive disease (PVOD) is a rare cause of pulmonary hypertension. We aimed to systematically evaluate published cases of PVOD to provide an overview of their clinical presentation, management and prognosis to assist early identification and treatment. We conducted a literature search of PubMed and Embase databases for adult cases of ‘pulmonary veno‐occlusive disease’ and ‘pulmonary capillary haemangiomatosis’. Data collected included baseline demographics, medical history, clinical presentation, investigations performed, treatment and outcome. Kaplan–Meier survival analysis was used for overall survival with Cox‐hazards‐regression model used to evaluate treatment outcomes and prognostic factors. A total of 257 cases of PVOD from 113 articles were included in our analysis (mean age 45 ± 17 years, 54% females). Most frequent associations were smoking (28%), systemic sclerosis (10%) and mitomycin exposure (9%). Cardinal CT chest findings included ground glass opacities (75%), interlobular septal thickening (74%) and lymphadenopathy (51%); however, all three features were only seen in 23% (35/151). Median overall survival was 12 months (interquartile range, 3–48 months). Lung transplantation was the only treatment associated with improved survival (P = 0.006). Right ventricular dilatation (P = 0.005), increased mean pulmonary artery pressure (P = 0.01) and reduced 6‐minute walk distance (P = 0.04) were associated with poorer overall survival. This systematic review provides a clinically relevant overview of a rare and often fatal condition. There is need for early diagnosis and referral for consideration of lung transplantation, while recognising right ventricular dilatation and elevated pulmonary pressures portend poorer prognosis. PROSPERO international register CRD42024553829.

01 Mar 2025·Mayo Clinic Proceedings

Natural History of Tricuspid Valve Regurgitation

Article

Author: Scott, Christopher G ; Lara-Breitinger, Kyla M ; Chaliki, Hari P ; Kucuk, Hilal Olgun ; Anand, Vidhu ; Nkomo, Vuyisile T ; Pislaru, Sorin V ; Alabdaljabar, Mohamad S ; Kane, Garvan C ; Shapiro, Brian P

OBJECTIVETo evaluate the natural course of medically managed ≥ moderate tricuspid regurgitation (TR) of any etiology, identify factors linked to progression and regression, and assess long-term clinical consequences.METHODSRetrospective analysis of 4051 adults with ≥ moderate TR (57.0% moderate, 43.0% severe) from January 1, 2004, to December 31, 2016, having at least one follow-up echocardiogram 6 months or more later. TR change was defined as at least one grade shift in severity, and all-cause mortality was the primary endpoint.RESULTSAt 1 year, TR regressed in 1499 (37.0%) patients and progressed in 417 (10.3%). Of 1603 with ≥ moderate TR at 1 year, only 346 (21.6%) experienced regression after the first year. Among 586 patients in whom TR regressed to mild or less at 1-year, 285 (48.6%) developed significant TR again long-term. Factors associated with TR progression included atrial fibrillation (odds ratio [OR], 1.55), chronic kidney disease (OR, 1.44), right ventricular dilatation (OR, 1.77), right atrial dilatation (OR, 1.94), pulmonary hypertension (OR, 1.25), and those associated with regression were coronary artery disease, diabetes, hypertension, and left ventricle dysfunction. Mortality was highest in patients whose TR progressed to or remained severe (HRs, 1.73 and 1.92, respectively), followed by those with stable moderate (HR, 1.18), and was lowest in whom TR regressed to mild or less.CONCLUSIONIn patients with ≥ moderate TR, regurgitation severity improved in one-third and remained unchanged in half at 1 year. Additionally, 10% of patients with moderate TR progressed to severe TR. Severe TR at 1 year was associated with a worse prognosis, with approximately 70% of these being patients whose TR did not improve with medical therapy. Although most improvements occurred within the first year, a considerable number experienced a recurrence afterward.

News (Medical) associated with Cardiomyopathy, Right Ventricular Dilated

16 Mar 2021

·www.biospace.com

Imbio Receives FDA 510(k) Clearance for New Cardiothoracic Imaging Algorithm

MINNEAPOLIS, March 16, 2021 /PRNewswire/ -- Imbio, a leading provider of artificial intelligence (AI) solutions for medical imaging analysis, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its RV/LV Analysis™ algorithm. The RV/LV Analysis algorithm is a rapid, automated assessment of potential right ventricular dilation. The tool quickly and accurately measures the ventricles of the heart to provide the ratio of the maximum diameter of the right versus the left ventricle. The resulting RV/LV ratio is a key patient risk indicator for various pulmonary conditions such as pulmonary embolism (PE). RV/LV Analysis results are automatically available for clinicians without any additional work including a full report of quantitative findings added directly to the patient imaging study within minutes. "Imbio is proud to deliver this AI-driven algorithm to clinicians and our partners to support acute cases and assist in key treatment decisions for patients," said David Hannes, Imbio Chief Executive Officer. "Our automated RV/LV Analysis has the power to provide vital information and inform risk stratification in many acute cases. We believe that the routine use of the RV/LV Analysis in clinical practice can also enable more consistent, quantitative reporting of potential right heart strain for all CTPA exams." Quantitative evaluation of computed tomography (CT) images can be used to aid clinicians in the risk stratification of pulmonary and cardiopulmonary diseases. The imaging biomarkers for PE, for example, can be measured reliably and consistently for real-world use-cases. Additionally, varying causes of right ventricular dilatation may be captured earlier if RV/LV automation is routinely implemented within native clinical workflows. With the ability to run the automated analysis and have results available at the time of the initial clinical reading, it may potentially save reporting time as well. "Reporting right heart strain on CT pulmonary angiogram studies positive for pulmonary embolism, despite what we are inclined to think, is frequently done inconsistently, incorrectly or not at all. We have shown Imbio's RV/LV Analysis to work consistently in unselected real-world cases and have demonstrated how it could alter management, as well as potentially predict all-cause mortality. Used routinely, it has the potential to standardize risk stratification and augment clinical care in this important disease," said Dr. Jonathan Rodrigues, Radiologist at Royal United Hospitals Bath NHS Foundation Trust. About Imbio Imbio is a leader in fully-automated AI image analysis for acute and chronic pulmonary and cardiothoracic conditions. Imbio's solutions transform the way patients are discovered, diagnosed and treated, enabling physician productivity and more personalized care for patients. Imbio's solutions are fully automated, regulatory cleared and available through our global partners. For more information, please visit .

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Cardiomyopathy, Right Ventricular Dilated

Basic Info

Related

Analysis